Pliant Gets FDA Clearance INDA For PLN-101095 To Treat Solid Tumors

Clinical stage biotechnology company Pliant Therapeutics, Inc. (PLRX) Thursday announced FDA clearance for its Investigational New Drug or IND application for PLN-101095. The company said it expects to initiate the Phase 1 first-in-human study evaluating PLN-101095 in patients with solid tumors in the second quarter of 2023.

PLN-101095 is an oral, small molecule, dual selective inhibitor of avß8 and avß1 integrins in development for the treatment of solid tumors resistant to immune checkpoint inhibitors

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots. The US Food and Drug Administration has cleared cultivated chicken developed by GOOD Meat Inc., the cultivated meat division of alternative foods startup Eat Just Inc. This is FDA's second pre-market consultation for a human food made from cultured animal cells after UPSIDE Foods. GOOD Meat is now required to meet Federal requirements including approvals from the US Department of Agriculture. A group of 23 U.S. states attorneys general have asked South Korean car manufacturers Hyundai Motor and Kia Corp. to take action more quickly to solve problems with millions of U.S. vehicles facing theft. The issue is related to the companies' failure to equip vehicles with anti-theft immobilizers, which has been a standard equipment on vehicles sold by other major manufacture
Follow RTT